SIMONA SOVERINI

ASSISTANT PROFESSOR

University of Bologna

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Simona Soverini is an Assistant Professor at the University of Bologna, Italy. Her research primarily focuses on hematological malignancies, specifically chronic myeloid leukemia (CML) and systemic mastocytosis. Recent publications include investigations into treatment resistance in CML and the therapeutic potential of targeting specific molecular pathways in cancer. Dr. Soverini is actively contributing to the understanding of prognostic factors and novel treatment strategies in these areas.

Articles (16)

Year:

2025

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (5)

Chiara Sartor

ITALY

View details

Elisabetta Abruzzese

UNIVERSITY TOR VERGATA

ITALY

View details

Cecilia Monaldi

Universitá degli Studi Magna Græcia di Catanzaro Dipartimento di Medicina Sperimentale e Clinica

ITALY

View details

Fabio Guolo

University of Genova

ITALY

View details

Margherita Martelli

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

SIMONA SOVERINI

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database

How I Evaluate and Treat Resistance and Relapse in CML

SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted

Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia

Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia

CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies

Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells

Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph<SUP>+</SUP> acute lymphoblastic leukemia

Non BCR::ABL1 Mutations in CML: Do They Matter?

Next‐generation sequencing improves BCR‐ABL1 mutation detection in Philadelphia chromosome‐positive acute lymphoblastic leukaemia

BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS

Next‐generation sequencing for BCR‐ABL1 kinase domain mutations in adult patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A position paper

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Collaborators (5)

Chiara Sartor

Elisabetta Abruzzese

Cecilia Monaldi

Fabio Guolo

Margherita Martelli

Make your next move.